middle.news
CLINUVEL Advances SCENESSE® for Adolescents with EPP, Reports Consistent Safety
9:20am on Monday 2nd of June, 2025 AEST
•
Pharmaceuticals
Read Story
CLINUVEL Advances SCENESSE® for Adolescents with EPP, Reports Consistent Safety
9:20am on Monday 2nd of June, 2025 AEST
Key Points
CUV052 study confirms SCENESSE® safety profile in adolescents matches adults
Pharmacokinetic data show higher but consistent drug exposure in adolescents
All eligible adolescent patients opted for continued treatment under special access
Data to underpin SCENESSE® label extension filing in second half of 2025
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
CLINUVEL PHARMACEUTICALS (ASX:CUV)
OPEN ARTICLE